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Poster Session I S245at our institution from 1998 to 2009. Most received Cy/TBI (97%)
based regimens. Ph1 group was older, median age 42 yrs. vs. 38
yrs, p 5 0.02. The 2 groups were balanced in distribution of condi-
tioning regimen, donor and stem cell source, HLAmatch, CMV sta-
tus, and WBC at diagnosis. 73% of the Ph1 were transplanted in
CR1, vs. 37% of the Ph- (p 5 0.0001). There was no difference in
time to neutrophil/platelet engraftment, grade II-IV acute GVHD
(28% vs. 31%), and chronic GVHD (53% vs. 51%) in the Ph1 vs.
Ph- groups, respectively. 3-year cumulative incidence of non-relapse
mortality and relapse (as competing risks) were 24% vs. 29% (p 5
0.66) and 34% vs. 41% (p5 0.56), for Ph1 vs. Ph- patients, respec-
tively. With median follow-up of 36 and 48 months after transplant,
there was no difference in 3-year progression free survival (PFS) and
3-year overall survival (OS) from time of transplant for Ph1 and Ph-
patients (PFS: 40% vs. 32%, p5 0.53; OS: 48% vs. 34%, p5 0.36).
To adjust for more patients in the Ph1 group being transplanted in
CR1, we also assessed survival from time of ALL diagnosis. 3-year
PFS and OS from time of ALL diagnosis for the Ph1 and Ph- pa-
tients were similar (PFS 48% vs. 48%, p 5 0.67; OS 50% vs. 49%,
p 5 0.93). In subset analyses restricted to patients transplanted in
CR1, 3-year PFS and OS were also similar in Ph1 vs. Ph- patients
(PFS: 51% vs. 35% p 5 0.59; OS: 53% vs. 40% p 5 0.58, respec-
tively). In multivariable models, more recent year of transplant was
associated with an improvement in PFS (HR 0.88, 95% CI 0.77-
0.99, p 5 0.04), and a trend toward better OS (HR 0.88, 95% CI
0.77-1.01, p 5 0.06) in the Ph1, but not Ph- cohort. There was
a trend towards improved 3-year OS for all patients transplanted af-
ter 2001, the year of imatinib approval, (OS5 42%) vs. before 2001
(OS 5 26%), P 5 0.15. In competing risks regression modeling,
WBC at diagnosis . 100K and bone marrow graft (vs. PBSC)
were significant factors associated with increased relapse in Ph1 pa-
tients. Our data suggest that followingmyeloablative allo-SCT, Ph1
ALL patients have similar outcomes compared to patients with Ph-
ALL, even when adjusted for disease stage at time of transplant.248
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMENS (RTC)
COMPARED WITH STANDARD MYELOABLATIVE CONDITIONING PRIOR
TO ALLOGENEIC STEM CELL TRANSPLANTATION IN AML AND MDS;
RTC HAS MORE FAVORABLE TOXICITY PROFILE BUT MORE LIMITED
LEUKEMIA CONTROL IN ADVANCED DISEASE
Shimoni, A., Rand, A., Shem-Tov, N., Volchek, Y., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic stem cell transplantation (SCT) is a curative therapy
for patients (pts) with AML and MDS. Standard myeloablative con-
ditioning (MAC) is associated with high rates of non-relapse mortal-
ity (NRM). Reduced-intensity conditioning reduces NRM but
relapse rates are higher. Reducing toxicity without compromising
SCT efficacy could be of a significant benefit. Novel reduced toxicity
myeloablative regimens (RTC) such as fludarabine with myeloabla-
tive doses of busulfan or treosulfan were designed to achieve this
goal, however their relative merits in different settings are not well
established. We analyzed SCT outcomes in a group of 252 pts
[AML-199 (66 secondary), MDS-53], median age 50 (17-76), given
SCT from related (n 5 144) or unrelated donors (n 5 108). Disease
status at SCT was defined as early (n5 81), intermediate (n5 54) or
advanced (n 5 117) by CIBMTR criteria. Eligible pts were given
MAC (BuCy, n5 90). Pts considered at high risk for NRM, but still
eligible for myeloablation were given RTC (n5 162). This group in-
cluded older pts (median age 55 Vs 39 years), more pts with comor-
bidity index . 2 (19% Vs 5%) and more unrelated donors. With
median follow-up of 36 months (1-129), 119 are alive, 52 had
NRM and 81 died of relapse. The 5-year overall survival (OS) is
41% (95CI, 34-48). It was 43% and 40% after MAC and RTC, re-
spectively (p 5 NS). NRM was 21% in both and relapse was 36%
and 39%, respectively (p5NS). Multivariable analysis (MVA) iden-
tified advanced disease as the major adverse factor for OS (HR 2.3, p
\ 0.001). Age . 50 and MAC were risk factors for NRM and ad-
vanced disease for relapse. The conditioning regimen had prognostic
significance in certain settings. Pts with MDS/2AML had better OS
after RTC than MAC; 49% and 37%, respectively (p5 0.07). MAC
(HR 1.9, P 5 0.03) and comorbidity index (HR 1.6, p 5 0.05) were
adverse prognostic factors. These pts were particularly more suscep-
tible to NRM with MAC. Pts with early AML had a trend for betterOSwithRTC; 75%and 47%, respectively (p5NS).MAChad a sur-
vival advantage in pts with intermediate-advanced disease, 45% and
22%, respectively (p5 0.06). This was due to higher relapse rate af-
ter RTC, 58% and 33%, respectively (p5 0.02). In conclusion, RTC
allows SCT in pts at higher risk for NRM with outcomes that are
similar to MAC in eligible pts. RTC may have an advantage in
MDS/2AML and possibly in early AML due to reduction of
NRM. However, MAC has an advantage in more advanced AML
due to better leukemia control.249
MULTI-DIMENSIONAL RESISTANCE PHENOTYPE ALLOWS QUIESCENT
LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR
TREATMENT TO ESCAPE FROM IMMUNOLOGICAL INTERVENTIONSWITH
ALLOREACTIVE T CELLS AND NK CELLS
Jedema, I., vanDreunen, L., Hagedoorn, R.S., Falkenburg, J.H.F. Leiden
University Medical Center, Leiden, Netherlands
Chronic myeloid leukemia (CML) is well responsive to various
therapeutic strategies, including tyrosine kinase inhibitors (TKI)
and allogeneic stem cell transplantation combined with donor lym-
phocyte infusion (DLI). Although initial complete responses are fre-
quently achieved, recurrenceof the disease is a commonphenomenon
occurring sometimes years after the therapeutic intervention(s). This
suggests that an initially undetectable subpopulation of leukemic pre-
cursor cells is capable of escaping therapy. In this study, we investi-
gated in detail the phenotype and apoptosis gene expression
fingerprint of this subpopulation of CML precursor cells residing af-
ter TKI treatment and immunological interventions with high affin-
ity cytotoxic donor T cells or NK cells. CD341 positive CML cells
were isolated from bone marrow and the number, phenotype, and
proliferative status of the CML cells residing after therapeutic inter-
vention(s) were measured by quantitative flowcytometry. Although
the majority of CML precursor cells and their malignant progeny
were efficiently targeted, a small subpopulation of non-dividing
CD34 bright cells, comprising on average 0.05-0.2% of the initial
CD341 population, showed cross-resistance to the different strate-
gies. In the absence of therapeutic pressure these cells were capable
of producingmalignant progeny. Phenotype analysis showed inferior
expression of HLA-class I and several adhesion molecules crucial for
the formationof a high avidity interactionwith immune effector cells,
includingCD54, CD58 andCD49d.Next, we compared the apopto-
sis gene expression fingerprint of this resistant subpopulation with
the profile of total CD341CMLprecursor cells and their proliferat-
ing malignant offspring using a quantitative array PCR containing
probes for 86 apoptosis-related genes (SABiosciences). This genetic
profiling revealed significant downregulation (4-182 fold) of crucial
players of the different main apoptosis pathways, including caspase-
3 and -8, Fas, TNFR, and different association molecules like
FADD, TRADD, and TRAFs, and a 4.8-6.2 fold upregulation of
the most important inhibitor of the death receptor pathway c-FLIP
(CFLAR). Interestingly, we observed a 55 fold downregulation of
the TKI-targeted fusion gene partner Abl1. These data show that
a subpopulation of CML precursor cells with potential self-renewal
capacity harbors a multi-dimensional resistance phenotype allowing
them to escape from different therapeutic strategies.250
SUCCESSFUL MANAGEMENT OF REFRACTORY/RECURRENT ACUTE MYE-
LOID LEUKEMIA BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION AND PROPHYLACTIC IMMUNOTHERAPY
Wang, J.-B., Wu, T., Da, W.-M., Sun, Y., Zhao, Y.-L., Cao, X.-Y.,
Yin, Y.-M., Lu, Y., Zhou, J.-R., Gao, Y.-Q., Zhang, J.-P., Luo, R.-
M., Zhang, Y.-C., Ji, S.-Q., Lu, D.-P., Tong, C.-R. Beijing Daopei
Hospital, Beijing, China
Our previous study has shown that donor’s dendritic cell-primed
cytokine-induced killer cell (DC-CIK) is a safe and effective thera-
peutic mean in management of early leukemia recurrence after allo-
geneic hematopoietic stem cell transplantation (HSCT) (JB Wang,
et al.ASH 2008). In present clinical study, the efficacy of refrac-
tory/recurrent acute myeloid leukemia (AML) salvaged by HSCT
and prophylactic immunotherapy is evaluated. From September
